Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04055493 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04055493 · ClinicalTrials.gov record · last posted 2026-05-11

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Study acronym: ADAPTcycle
StatusActive, Not Recruiting
PhasePhase 3
Started2019-07-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of-care chemotherapy (followed by adjuvant endocrine therapy).

Protocol amendment history 1 change detected by DataLookout

2026-08-09
Sponsor changed: West German Study Group → Women's Cancer Study Group GmbH
WasWest German Study Group
NowWomen's Cancer Study Group GmbH
Trial Details
NCT Number NCT04055493
Lead Sponsor West German Study Group
Collaborators: Novartis, Genomic Health®, Inc.
Conditions Breast Cancer Female
Enrollment 1,684 participants
Start Date 2019-07-02
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-11